The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.
An article from
Obesity drugs
The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.
Published Sept. 8, 2026
Moonwalk Biosciences is led by CEO Alex Aravanis (left), and Justin Valley, chief operating officer; Elaine Cheung, chief business officer; and Arash Jamshidi, president and chief technology officer.
Moonwalk Biosciences raises $70M Series B to push MW-101, an siRNA obesity drug aimed at fat tissue, toward a 2027 trial start.
Key catalysts, including growing confidence around Amgen’s MariTide obesity program, could transform the name into a growth story.
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that…
Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
A new startup is making a bold move in the world of obesity drug development: It’s not working with the GLP-1 target that has…
With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. | Roche is taking a less-trodden…
